What Lemonade Holders Got Wrong Before The Slide

If you had looked at Lemonade on 1 January 2026 and decided to wait for clearer proof that its AI-heavy insurance model was working, your patience would have spared you a rough ride. Holding Lemonade from the start of the year would have meant a 38.8% loss, including dividends. With that kind of drawdown now on record, which early assumptions or warnings in the 2024 and 2025 commentary deserved closer attention?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

Lemonade is not the only name tied to this theme. Zero in on 39 profitable AI stocks that aren't just burning cash and compare how each one is priced.

The Two Lemonade Stories Investors Were Weighing

The shares cost US$71.18 at the start of the period, and anyone looking at Lemonade then was really choosing between two very different stories that both sounded plausible.

On the optimistic side, the November 2024 Narrative put Fair Value at US$77.14. It was built on in-force premiums of US$889 million, five consecutive quarters of loss ratio improvement, and an assumption that revenue could grow 25.2% with profit margins reaching 15.0% over 5 years.

The more cautious December 2025 view pinned Fair Value at US$45.12 and assumed faster 44.9% revenue growth but only an 11.0% margin. It also warned that economic pressures, rising claim costs, and higher regulatory scrutiny on AI could strain profitability and add compliance expenses.

What The Results Changed For The Lemonade Thesis

Lemonade’s Q2 2026 report showed revenue at US$294.4 million against US$164.1 million a year earlier, with the loss narrowing slightly from US$43.9 million to US$43.4 million and net margin improving from -26.8% to -14.7%. The business still reported a loss, so the profitability part of the optimistic case stayed unproven and the evidence cut both ways.

The key assumption was that AI-driven scale would translate into clear, reported profitability. When you look at another growth story, stress test that same claim by tracking whether revenue progress comes with a firmly positive net margin, not just a smaller loss.

What Lemonade’s Lower Price Is Asking You To Believe

Lemonade trades at US$46.46 today, after a 38.8% loss from the start of the year. The selected Narrative places Fair Value above that level and argues that the market is undercharging for what its AI-heavy model and product breadth could deliver if the thesis plays out.

The core consideration is whether Lemonade can convert its current AI, underwriting and product expansion into sustainably stronger loss ratios and margins. Anyone buying today would be assuming that this operating improvement can be achieved and then maintained through tougher competition and changing claim costs.

"Leveraging proprietary AI and tech-enabled expansion across diverse insurance lines and regions positions Lemonade for sustained revenue growth, efficiency gains, and competitive advantage."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Find Your Own Contrarian Opportunity

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 31% below our estimate - turns tight offshore vessel availability into higher day rates on contracts.
• Company 2 - 34% below our estimate - advances late-stage genetic therapies for kidney, blood and endocrine disorders.
• Company 3 - 36% below our estimate - handles cross-border platform payments as users adopt more digital transaction options.

Three companies from the same screener. Open every one of the 28 undervalued companies on it →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com